Heier Margit, Moebus Susanne, Meisinger Christa, Jöckel Karl-Heinz, Völzke Henry, Döring Angela, Alte Dietrich
Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Institute of Epidemiology, Neuherberg, Germany.
Maturitas. 2009 Jan 20;62(1):9-15. doi: 10.1016/j.maturitas.2008.10.002. Epub 2008 Nov 22.
To determine regional variations in the prevalence and applied therapy regimes of current menopausal hormone therapy (HT) in Germany.
Three population-based surveys, analysing data of 45-74 years old women, were compared: The Study of Health in Pomerania (SHIP; 1123 participants; northeast Germany, October 1997-May 2001), Cooperative Health Research in the Augsburg Region Survey 2000 (KORA; 1253 participants; south Germany, October 1999-April 2001) and Heinz Nixdorf Recall Study (HNR; 2257 participants; west Germany, December 2000-August 2003). A standardized interview technique provided data on current medication.
The age-standardized prevalence of HT was 17.0% (95% confidence interval (CI): 14.9-19.1) in SHIP, 25.9% (95% CI: 23.6-28.3) in KORA and 24.7% (95% CI: 22.9-26.4) in HNR. Mean average time of intake of HT was 5.1 (SHIP), 7.5 (KORA) and 10.1 years (HNR). The use of estrogen plus progestogen combinations was equally common in all three surveys with proportions of about 15%, the use of unopposed estrogen in KORA and HNR was twice as high as in SHIP. In all three surveys oral estradiol was taken most often. Transdermal estradiol was preferred by KORA women whereas conjugated estrogens were taken most frequently by HNR women.
Compared to northeast Germany HT was more often applied in the south and west of Germany. HT as long-term therapy was more common in West than in East Germany. In each study region there was a specific pattern of used HT components.
确定德国目前更年期激素治疗（HT）的患病率及应用治疗方案的地区差异。
比较了三项基于人群的调查，分析45 - 74岁女性的数据：波美拉尼亚健康研究（SHIP；1123名参与者；德国东北部，1997年10月 - 2001年5月）、奥格斯堡地区2000年合作健康研究（KORA；1253名参与者；德国南部，1999年10月 - 2001年4月）和海因茨·尼克斯多夫召回研究（HNR；2257名参与者；德国西部，2000年12月 - 2003年8月）。采用标准化访谈技术获取当前用药数据。
SHIP中HT的年龄标准化患病率为17.0%（95%置信区间（CI）：14.9 - 19.1），KORA中为25.9%（95%CI：23.6 - 28.3），HNR中为24.7%（95%CI：22.9 - 26.4）。HT的平均服用时间在SHIP中为5.1年，KORA中为7.5年，HNR中为10.1年。雌激素加孕激素联合用药在所有三项调查中同样常见，比例约为15%，KORA和HNR中单纯雌激素的使用量是SHIP中的两倍。在所有三项调查中，口服雌二醇最为常用。KORA的女性更喜欢经皮雌二醇，而HNR的女性最常服用结合雌激素。
与德国东北部相比，HT在德国南部和西部应用更为频繁。作为长期治疗的HT在西德比东德更为常见。在每个研究地区，HT成分的使用都有特定模式。
